{"transactions":[{"id":2037282,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":117407,"kind":"person","name":"Salain Daniel","position":1,"cik":"0001824804","reported_name":"Salain Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-02-02T20:12:41.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":25400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer."}],"balance_after":25400,"derivative":{"exercise_price":5.21,"expiration_date":"2033-01-20","underlying":"Common Stock","underlying_shares":25400},"source":{"system":"sec-edgar","filing":"0001415889-23-001857","document":"form4-02032023_010231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000141588923001857/form4-02032023_010231.xml","form_type":"4"}},{"id":2051626,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":117407,"kind":"person","name":"Salain Daniel","position":1,"cik":"0001824804","reported_name":"Salain Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series Z Convertible Preferred Stock","published_at":"2023-01-19T21:46:38.000Z","date":"2023-01-17","kind":"exercise","acquired":false,"shares":22810,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share (\"Series Z Preferred Stock\") converted into shares of common stock of the Issuer, par value $0.001 per share (\"Common Stock\"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share (\"Series Z Preferred Stock\") converted into shares of common stock of the Issuer, par value $0.001 per share (\"Common Stock\"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share (\"Series Z Preferred Stock\") converted into shares of common stock of the Issuer, par value $0.001 per share (\"Common Stock\"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share (\"Series Z Preferred Stock\") converted into shares of common stock of the Issuer, par value $0.001 per share (\"Common Stock\"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share (\"Series Z Preferred Stock\") converted into shares of common stock of the Issuer, par value $0.001 per share (\"Common Stock\"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Reflects a 1-for-17 reverse stock split, which became effective on January 17, 2023 at 4:59 pm Eastern Time."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1341764},"source":{"system":"sec-edgar","filing":"0001104659-23-005135","document":"tm233989-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/861838/000110465923005135/tm233989-3_4seq1.xml","form_type":"4"}},{"id":2051625,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":117407,"kind":"person","name":"Salain Daniel","position":1,"cik":"0001824804","reported_name":"Salain Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-01-19T21:46:38.000Z","date":"2023-01-17","kind":"exercise","acquired":true,"shares":1341764,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share (\"Series Z Preferred Stock\") converted into shares of common stock of the Issuer, par value $0.001 per share (\"Common Stock\"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share (\"Series Z Preferred Stock\") converted into shares of common stock of the Issuer, par value $0.001 per share (\"Common Stock\"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-17 reverse stock split, which became effective on January 17, 2023 at 4:59 pm Eastern Time."}],"balance_after":1469482,"source":{"system":"sec-edgar","filing":"0001104659-23-005135","document":"tm233989-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000110465923005135/tm233989-3_4seq1.xml","form_type":"4"}},{"id":2149046,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":117407,"kind":"person","name":"Salain Daniel","position":1,"cik":"0001824804","reported_name":"Salain Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series Z Convertible Preferred Stock","published_at":"2022-09-30T21:49:13.000Z","date":"2022-09-28","kind":"grant","acquired":true,"shares":22810,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. (\"Idera\") and Aceragen, Inc. (\"Aceragen\"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the \"Merger\"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share (\"Common Stock\") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 (\"Series Z Preferred Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. (\"Idera\") and Aceragen, Inc. (\"Aceragen\"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the \"Merger\"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share (\"Common Stock\") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 (\"Series Z Preferred Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations."}],"balance_after":22810,"derivative":{"underlying":"Common Stock","underlying_shares":22810000},"source":{"system":"sec-edgar","filing":"0001104659-22-104796","document":"tm2227191-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/861838/000110465922104796/tm2227191-8_4seq1.xml","form_type":"4"}},{"id":2149045,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":117407,"kind":"person","name":"Salain Daniel","position":1,"cik":"0001824804","reported_name":"Salain Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.001","published_at":"2022-09-30T21:49:13.000Z","date":"2022-09-28","kind":"grant","acquired":true,"shares":2171214,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. (\"Idera\") and Aceragen, Inc. (\"Aceragen\"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the \"Merger\"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share (\"Common Stock\") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 (\"Series Z Preferred Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. (\"Idera\") and Aceragen, Inc. (\"Aceragen\"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the \"Merger\"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share (\"Common Stock\") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 (\"Series Z Preferred Stock\")."}],"balance_after":2171214,"source":{"system":"sec-edgar","filing":"0001104659-22-104796","document":"tm2227191-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000110465922104796/tm2227191-8_4seq1.xml","form_type":"4"}},{"id":2949778,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":117407,"kind":"person","name":"Salain Daniel","position":1,"cik":"0001824804","reported_name":"Salain Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CTOO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-12-10T22:10:59.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares on January 8, 2021 and each month thereafter until option is fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":35000,"derivative":{"exercise_price":23.66,"expiration_date":"2030-12-07","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-20-062754","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534133/000120919120062754/doc4.xml","form_type":"4"}}]}